Abstract library

27 results for "nonfunctional NET".
#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Rodney Pommier
#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni
#1597 The Diagnostic and Prognostic Value of Plasma CgA in Nonfunctional Pancreatic Neuroendocrine Neoplasms
Introduction: Controversies still remain on the diagnostic and prognostic value of CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
#2185 Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC-PET/CT: Initial Data of a Prospective Study
Introduction: Predicting aggressive behavior of NF PNET still remains controversial. It is known that lymph node metastases are rare but possible also on small (1-2 cm) NF-PNET. Positive 18F-FDG-PET/CT avidity is associated with poor prognosis in NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Susanna Majala
#750 Management of Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor
Introduction: Nonfunctional NETs themselves present in generally two ways, either with symptoms caused by the tumor compression of other organs, or found by imaging test performed for other reasons.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ivan Vasiliev
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1360 Development and Validation of Nomogram in Predicting Individualized Postoperative Survival for Nonfunctional Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
Introduction: NA
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ma H, Feng J, Xu X, ...
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#1897 Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms - A Multi-Institutional Study
Introduction: Malignant potential of sporadic nonmetastatic nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to preoperatively predict
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Pr Sebastien Gaujoux
Keywords: pancreatic NETs
#1258 Expressions of CK 19 and CD117 in Hepatic Metastatic Pancreatic Nonfunctional Neuroendocrine Neoplasms
Introduction: The expressions of CK19 and CD117 in pancreatic neoruendocrine neoplasms were considered dismal prognostic factors in some studies, but inconsistent in others.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Bao Xin
Authors: Xin B, Lou W, Ji Y, Xie Y, ...
Keywords: CK19, CD117, pNEN, LM, TMA
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.